PBYI News and Press, Puma Biotechnology Inc From 11/06/19

Puma Biotechnology, Inc. (PBYI) Q3 2019 Earnings Conference Call November 6, 2019, 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Conference Call Participants Alethia Young - Cantor...

Gainers: CNFR   +22.2% . VNDA   +19.9% . IFRX   +18.1% . DXCM   +17.5% . IVC   +15.6% . More news on: Conifer Holdings, Inc., Vanda Pharmaceuticals Inc., InflaRx N.V., Stocks on the move, Read more ...

Puma Biotechnology (NASDAQ: PBYI ) Q3 results : More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Puma Biotechnology (NASDAQ: PBYI ): Q3 Non-GAAP EPS of -$0.12 beats by $0.33 ; GAAP EPS of -$0.44 beats by $0.27 . Revenue of $56.4M (-9.9% Y/Y) misses by $3.81M . Shares -16% . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stock...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019 compared to the third quarter 2018. Product revenue, net consists entir...

AAOI , AEL , AIMT , ALB , ANGI , ANSS , ASRT , ATO , ATSG , AXGN , BAND , BIDU , BL , BNFT , BRKS , CECO , CNDT , COLL , CTL , CVNA , CXW , DAR , DCP , DVAX , DXCM , DXPE , EBS , ECPG , EGAN , ENS , EOG , EQH , ERI , ET , EVRG , EXPE , FG , FISV , FIT ...

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX® (neratinib) for the extended adjuvant treatment of adult patie...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m. MST (9:55 a.m. PST, 12:55 p.m. EST) on Tuesday, November 12, at the Cr...

Investors have all but given up on Puma Biotechnology (NASDAQ: PBYI) , which is really saying something. Two short years ago, the company's lone drug product, Nerlynx, was expected to generate peak annual sales of at least $1.25 billion. Wall Street analysts had price targets as high as $125 ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...